Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis

BACKGROUND AND AIMS: Vedolizumab is an anti-α4β7 antibody approved for the treatment of ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the u...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Crohns Colitis
Hlavní autoři: Veny, Marisol, Garrido-Trigo, Alba, Corraliza, Ana M, Masamunt, Maria C, Bassolas-Molina, Helena, Esteller, Miriam, Arroyes, Montserrat, Tristán, Eva, Fernández-Clotet, Agnès, Ordás, Ingrid, Ricart, Elena, Esteve, Maria, Panés, Julian, Salas, Azucena
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7944518/
https://ncbi.nlm.nih.gov/pubmed/32926095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjaa178
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky